159,407 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Purchased by Barclays PLC

Barclays PLC bought a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 159,407 shares of the company’s stock, valued at approximately $577,000.

Other hedge funds also recently modified their holdings of the company. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA during the fourth quarter worth approximately $36,000. Victory Capital Management Inc. acquired a new stake in Atyr PHARMA during the 4th quarter worth $37,000. Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA during the 4th quarter valued at $39,000. ExodusPoint Capital Management LP acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at $61,000. Finally, Farther Finance Advisors LLC bought a new position in shares of Atyr PHARMA in the 4th quarter worth $88,000. Institutional investors own 61.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ATYR shares. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research report on Friday, March 14th. Finally, Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Stock Up 5.7 %

Shares of Atyr PHARMA stock opened at $3.34 on Friday. Atyr PHARMA INC has a 1 year low of $1.42 and a 1 year high of $4.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The company has a market capitalization of $296.79 million, a P/E ratio of -3.55 and a beta of 0.79. The business has a 50-day moving average of $3.26 and a two-hundred day moving average of $3.40.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. As a group, equities analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.